347 related articles for article (PubMed ID: 19596183)
41. IL-2-independent generation of FOXP3(+)CD4(+)CD8(+)CD25(+) cytotoxic regulatory T cell lines from human umbilical cord blood.
Nakamura S; Suzuki M; Sugimoto A; Tsuji-Takayama K; Yamamoto M; Otani T; Inoue T; Harashima A; Okochi A; Motoda R; Yamasaki F; Orita K; Kibata M
Exp Hematol; 2007 Feb; 35(2):287-96. PubMed ID: 17258077
[TBL] [Abstract][Full Text] [Related]
42. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses.
Sela U; Dayan M; Hershkoviz R; Cahalon L; Lider O; Mozes E
Eur J Immunol; 2006 Nov; 36(11):2971-80. PubMed ID: 17051618
[TBL] [Abstract][Full Text] [Related]
43. Immune tolerance: what is unique about the liver.
Tiegs G; Lohse AW
J Autoimmun; 2010 Feb; 34(1):1-6. PubMed ID: 19717280
[TBL] [Abstract][Full Text] [Related]
44. CD4(+) T regulatory cells are more resistant to DNA damage compared to CD4(+) T effector cells as revealed by flow cytometric analysis.
Winzler C; Fantinato M; Giordan M; Calore E; Basso G; Messina C
Cytometry A; 2011 Nov; 79(11):903-11. PubMed ID: 22015731
[TBL] [Abstract][Full Text] [Related]
45. The effects of Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody in DSS-induced mice colitis.
Chen J; Xie L; Toyama S; Hünig T; Takahara S; Li XK; Zhong L
Int Immunopharmacol; 2011 May; 11(5):610-7. PubMed ID: 21163250
[TBL] [Abstract][Full Text] [Related]
46. CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidney.
Zhang JL; Sun DJ; Hou CM; Wei YL; Li XY; Yu ZY; Feng JN; Shen BF; Li Y; Xiao H
Transpl Immunol; 2010 Oct; 24(1):17-25. PubMed ID: 20850528
[TBL] [Abstract][Full Text] [Related]
47. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance.
Vargas-Rojas MI; Crispín JC; Richaud-Patin Y; Alcocer-Varela J
Lupus; 2008 Apr; 17(4):289-94. PubMed ID: 18413409
[TBL] [Abstract][Full Text] [Related]
48. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide.
Sharabi A; Dayan M; Zinger H; Mozes E
J Clin Immunol; 2010 Jan; 30(1):34-44. PubMed ID: 19756988
[TBL] [Abstract][Full Text] [Related]
49. Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases.
Sharabi A; Mozes E
Immunotherapy; 2009 May; 1(3):385-401. PubMed ID: 20635958
[TBL] [Abstract][Full Text] [Related]
50. Systemic lupus erythematosus exhibits a dynamic and continuum spectrum of effector/regulatory T cells.
Mesquita D; de Melo Cruvinel W; Araujo J; Pucci F; Salmazi K; Kallas E; Andrade L
Scand J Rheumatol; 2011 Jan; 40(1):41-50. PubMed ID: 20936986
[TBL] [Abstract][Full Text] [Related]
51. Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells.
Yang Y; Paik JH; Cho D; Cho JA; Kim CW
Int Immunopharmacol; 2008 Apr; 8(4):542-7. PubMed ID: 18328445
[TBL] [Abstract][Full Text] [Related]
52. Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1.
Sthoeger Z; Sharabi A; Zinger H; Asher I; Mozes E
Clin Immunol; 2018 Dec; 197():34-39. PubMed ID: 30170030
[TBL] [Abstract][Full Text] [Related]
53. Regulatory T cells in systemic lupus erythematosus.
Ohl K; Tenbrock K
Eur J Immunol; 2015 Feb; 45(2):344-55. PubMed ID: 25378177
[TBL] [Abstract][Full Text] [Related]
54. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E
Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008
[TBL] [Abstract][Full Text] [Related]
55. Neem leaf glycoprotein inhibits CD4+CD25+Foxp3+ Tregs to restrict murine tumor growth.
Chakraborty T; Bose A; Barik S; Goswami KK; Banerjee S; Goswami S; Ghosh D; Roy S; Chakraborty K; Sarkar K; Baral R
Immunotherapy; 2011 Aug; 3(8):949-69. PubMed ID: 21843083
[TBL] [Abstract][Full Text] [Related]
56. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus.
Zhang L; Bertucci AM; Ramsey-Goldman R; Burt RK; Datta SK
J Immunol; 2009 Nov; 183(10):6346-58. PubMed ID: 19841178
[TBL] [Abstract][Full Text] [Related]
57. A peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3.
Sela U; Dayan M; Hershkoviz R; Lider O; Mozes E
J Immunol; 2008 Feb; 180(3):1584-91. PubMed ID: 18209054
[TBL] [Abstract][Full Text] [Related]
58. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model.
Sharabi A; Luger D; Ben-David H; Dayan M; Zinger H; Mozes E
J Immunol; 2007 Oct; 179(8):4979-87. PubMed ID: 17911582
[TBL] [Abstract][Full Text] [Related]
59. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells.
Scheinecker C; Bonelli M; Smolen JS
J Autoimmun; 2010 Nov; 35(3):269-75. PubMed ID: 20638240
[TBL] [Abstract][Full Text] [Related]
60. Effect of Regulatory T Cells on Promoting Apoptosis of T Lymphocyte and Its Regulatory Mechanism in Sepsis.
Luan YY; Yin CF; Qin QH; Dong N; Zhu XM; Sheng ZY; Zhang QH; Yao YM
J Interferon Cytokine Res; 2015 Dec; 35(12):969-80. PubMed ID: 26309018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
